All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Selina M. Luger, University of Pennsylvania, Philadelphia, US. We asked: What are the current challenges in ALL that need to be addressed?
What are the current challenges in ALL that need to be addressed?
Here, she highlights a number of considerations regarding ALL treatment strategies:
1) Should all patients receive transplant for the treatment of ALL?
2) Do all patients with Philadelphia chromosome-positive ALL require intensive chemotherapy?
3) Are there patients with Philadelphia chromosome-negative ALL who demonstrate good responses without chemotherapy?
4) Should targeted agents be incorporated into chemotherapy regimens?
Selina M. Luger concludes by highlighting the lack of targeted agents available for T-cell ALL and outlines emerging therapeutics in this setting.
Genetic markers in the prognosis of patients with ALL
Despite much research, the mutational landscape of patients with acute lymphoblastic leukemia (ALL) remains relatively poorly characterized, especially for rarer subtypes.
Recurrent immature Ig gene rearrangements in TP53-mutated B-precursor adult ALL
During the premature stage of lymphopoiesis, immunoglobulin (Ig) and T-cell receptor (TCR) genes undergo rearrangements — key mechanisms of the physiological process....
Subscribe to get the best content related to ALL delivered to your inbox